A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of the fixed dose combination of Empagliflozin 10 mg/Linagliptin 5 mg compared with Empagliflozin 10 mg alone and the efficacy and safety of Empagliflozin 25 mg/Linagliptin 5 mg compared with Empagliflozin 25 mg alone each administered orally once daily over 24 weeks in patients with type 2 diabetes mellitus who have insufficient glycaemic control after 16 weeks of treatment with Empagliflozin 10 mg or Empagliflozin 25 mg once daily and maximum tolerated dose of metformin IR.